Title: "determination of 5-fluoro-2'-deoxycytidine (FDCYD), selected downstream metabolites (fdurd, FU), and tetrahydrouridine (THU) levels in human." period of performance 5/1/2018 - 8/31/2021
Ended Awarded Last action
- Contract number
- HHSN26100004
- Awardee
-
University Of Pittsburgh - Of The Commonwealth System Of Higher Education UEI MKAGLD59JRL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $27,605
Award facts
- Opportunity
-
- N02CM6700011 Solicitation number
- Preclinical Pharmacokinetic and Pharmacology Evaluations of Agents Being Developed for Cancer Patients Award Notice · Posted Feb 5, 2016
- Preclinical Pharmacokinetic and Pharmacological Studies Being Developed for Cancer Patients Award Notice · Posted Oct 6, 2015
- Contract value 100% obligated
- $27,605.09 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Pittsburgh, PA 15213, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$3,254 | |
| Original award | $30,859 |
About this award
This is a federal contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the University of Pittsburgh. The contract, valued at $27,605.09, is for the determination of 5-fluoro-2'-deoxycytidine (FDCYD), selected downstream metabolites, and tetrahydrouridine (THU) levels in human samples. The period of performance is from May 1, 2018, to August 31, 2021. This contract is a delivery order under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients Indefinite Delivery Contract (IDC), which allows the NCI to rapidly initiate new preclinical studies in support of its mission to research, treat, and prevent infectious diseases. The contract does not have a set-aside designation.
Quick answers
Who was awarded contract HHSN26100004?
HHSN26100004 was awarded to University Of Pittsburgh - Of The Commonwealth System Of Higher Education by National Cancer Institute (National Institutes of Health) on May 1, 2018.
How much is contract HHSN26100004 worth?
The government has obligated $27,605 on HHSN26100004.
Is contract HHSN26100004 an order under another contract?
Yes. HHSN26100004 is a delivery order under HHSN261201600022I, an indefinite delivery contract, on Pharmacokinetic and Pharmacology Evaluations for Cancer Patients.
Was contract HHSN26100004 competed?
The extent of competition for HHSN26100004 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award